John Libbey Eurotext

Brivaracetam for dyskinetic cerebral palsy Volume 24, issue 3, June 2022

Video

  • Brivaracetam for dyskinetic cerebral palsy

Figures

  • Figure 1.
Authors
1 Department of Biomedical Sciences, School of Health Sciences, International Hellenic University, Thessaloniki, Greece
2 Laboratory of Clinical Neurophysiology, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki, Greece
3 1st Department of Neurology, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki, Greece
4 3rd Department of Neurology, Aristotle University of Thessaloniki, Papanikolaou General Hospital, Thessaloniki, Greece
5 Medical School, University of Cyprus, Nicosia, Cyprus
* Correspondence: Vasilios K. Kimiskidis

Cerebral palsy (CP) is one of the most common motor disabilities in childhood affecting about 3-4/1,000 children in United States [1]. CP comprises mixed movement disorders (i.e. dystonia, chorea and athetosis) that are caused by damage to the developing foetal brain and are often accompanied by disturbances of sensation, cognition, communication, perception and behaviour and epileptic seizures.We present a case on the efficacy of brivaracetam (BRV) therapy in a patient with dyskinetic CP, who was [...]